Repligen | RGEN - Ebitda


Repligen reported $39.54M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
Agilent USD 540M 74M Sep/2025
Align Technology USD 183.84M 19.77M Sep/2025
Bio Techne USD 103.42M 7.47M Dec/2025
BioMarin Pharmaceutical USD -24.17M 18.91M Dec/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Bruker USD 211.6M 207.4M Dec/2025
Charles River Laboratories USD 258.06M 24.83M Dec/2025
Danaher USD 2.13B 252M Dec/2025
Dentsply International USD 135M 32M Dec/2025
Exact Sciences USD 135.42M 2.8M Sep/2025
General Electric Aerospace USD 3.04B 185M Sep/2025
Henry Schein USD 291M 4M Dec/2025
Illumina USD 332M 12M Sep/2025
IQVIA Holdings USD 1.05B 97M Dec/2025
Mettler Toledo International USD 322.64M 26.75M Sep/2025
Myriad Genetics USD 10.3M 4.2M Sep/2025
OraSure Technologies USD -17.7M 4.06M Dec/2025
Pacific Biosciences Of California USD -35.4M 5.78M Sep/2025
Pfizer USD 6.08B 351M Sep/2025
Repligen USD 39.54M 3.61M Dec/2025
Revvity USD 248.91M 48.52M Dec/2025
Standard Biotools USD -16.54M 2.26M Sep/2025
Thermo Fisher Scientific USD 3.17B 335M Dec/2025
Waters USD 380.97M 85.83M Dec/2025
West Pharmaceutical Services USD 218.5M 5.4M Dec/2025